Presentations highlighting CRISPR genetic and epigenetic editing therapies, machine learning, and corporate updates at multiple industry-leading events in Fall 2025

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in a series of leading medical, scientific, and investor conferences during September and October 2025, highlighting the company’s latest platform and pipeline progress:

European Society of Cardiology (ESC) Congress

Madrid, Spain

September 1, 2025, between 11:15 AM and 12:00 PM CEST

Aarif Khakoo, M.D., M.B.A., Chief Scientific Officer and Head of Research and Development, will present “Preclinical proof of concept for STX-1200: potent LPA editing and Apo(a) knockdown via CasX-based gene editing” during a session titled “Molecular networks and emerging therapeutics in cardiac pathophysiology.”

Cantor Global Healthcare Conference

New York, NY

September 3-5, 2025

Benjamin Oakes, Ph.D., Co-founder and CEO, and David Parrot, M.B.A., CFO, will participate and be available for one-on-one meetings with investors.

Bank of America Healthcare Trailblazers Private Company Conference

Boston, MA

September 17, 2025

CFO David Parrot will participate and be available for one-on-one meetings with investors.

Genome Editing Therapeutics Summit (formerly known as CRISPR 2.0)

Boston, MA

September 30, 2025, 8:30 AM ET

Kai-Yuan Chen, Ph.D., Director of Data Science and Tech Platform at Scribe, will open the conference with a presentation titled “DeepXE: A Deep Learning Approach to Modeling & Designing Efficient CRISPR-CasX Guide RNAs for Therapeutics.” The talk will showcase DeepXE, the first predictive model approach for Scribe’s CasX-based genome editing platform.

Cell & Gene Meeting on the Mesa

Phoenix, AZ

October 6, 2025, 1:45 PM MST

CEO Benjamin Oakes will deliver a corporate presentation at the premier conference for cell and gene therapy innovation.

About Scribe Therapeutics

Scribe Therapeutics is revolutionizing medicine by developing optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. The company is on a mission to build the first CRISPR-based therapeutics that are effective and safe enough to transform everyone’s lifetime risk for disease. Scribe’s CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity, and deliverability, enabling the creation of therapies with a broader therapeutic window and safe for use as a preventative treatment. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825604203/en/